SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Seribantumab (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SHERLOC
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Merrimack Pharmaceuticals media release, top-line results are expected in the second half of 2018.
    • 08 Jan 2017 According to a Merrimack Pharmaceuticals media release, top-line results are expected by year-end 2018.
    • 08 Jan 2017 According to a Merrimack Pharmaceuticals media release, protocol has been amended to change the study to a smaller study with progression free survival as the primary endpoint.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top